In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

India’s Contract Development and Manufacturing Organization (CDMO) market is poised for exponential growth, expected to ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2025, subject to the employee's continued service with Mersana on each such vesting date. The RSU ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

Western drugmakers are striking more deals in China to access “bio-better” treatments for diseases from obesity to cancer, ...